Company Active LTD

Company profile

IHG Pharmaco Limited

IHG Pharmaco Limited is a UK company with status active founded in 2005.

CRN
05606880
Founded
2005
Age
20

Overview

Legal name
IHG PHARMACO LIMITED
Region
Unknown
Registered address
20-22 WENLOCK ROAD
LONDON
N1 7GU
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
12 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

26 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

28 Oct
2005

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2015
Funded years
2015, 2019, 2020, 2022
Age at first award
9 years

Projects

2022 Collaborative R&D Lead participant

Novel Biomarker Test with Treatment, to Predict and Prevent Miscarriage and Adverse Birth Outcomes in Ethnically Diverse Patient Populations.

1 Apr 2022 to 31 Mar 2025

Awarded
£980,001
Total cost £1,400,001

The project builds on earlier Innovate funded feasibility work and comprises manufacturing a prototype test for validation and stability testing, for an eventual manufactured form of a novel test for adverse pregnancy outcomes affecting mothers and children. This will include Black and Asian ethnicity patients who are at higher risk of these adverse outco...

2020 Collaborative R&D Lead participant

Developing mouthswab patient friendly testing combined with determining African/Asian incidence of a biomarker to reduce risks of adverse birth outcomes using a novel pharmacogenomic test

1 Nov 2020 to 30 Nov 2021

Awarded
£98,795
Total cost £98,795

COVID19 has required face to face contact with patients to be as limited as possible thus making obtaining clinical trial samples very difficult. The project comprises using mouthswabs to gain access to patients DNA to genotype for the incidence of a biomarker associated with adverse birth outcomes and include the results in a large clinical study. These ...

2019 Feasibility Studies Lead participant

Feasibility of Manufacturing a Reproductive Biomarker Test and Scoping for NHS Adoption in Primary Care

1 Aug 2019 to 31 Oct 2020

Awarded
£140,000
Total cost £200,000

The project comprises determining the feasibility of making a manufactured form of a diagnostic test that can utilise capillary electrophoresis to detect an important gene associated with human health.

2015 Vouchers Lead participant

capillary electrophoresis

1 Aug 2015 to 31 Jan 2016

Awarded
£5,000
Total cost £5,000

"To develop the test, supplier to prototype the assay to run on the ABI analyser as follows: The assay probes to be fluorescently labelled to produce clearer and ‘cleaner’ images to maximise assay resolution.Optimise polymer for non-denaturing run conditions Extract DNA from saliva and quantify Run assay and DNA from saliva on a long capillary using capil...

Product types

Collaborative R&D Feasibility Studies Vouchers